Rapport Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Rapport Therapeutics Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
/ 
Frequently asked questions
To buy Rapport Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Rapport Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Rapport Therapeutics Inc. is RAPP:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Rapport Therapeutics Inc. has its primary listing on NASDAQ. You can trade Rapport Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Rapport Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Rapport Therapeutics Inc. as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Rapport Therapeutics Inc. or others.